Oncodesign Precision Medicine S.A Logo

Oncodesign Precision Medicine S.A

Develops therapeutic and diagnostic solutions for resistant and metastatic cancers.

ALOPM | Euronext Access Plus

Overview

Corporate Details

ISIN(s):
FR001400CM63
LEI:
969500ZDX1IY47LDL876
Country:
France
Address:
18 RUE JEAN MAZEN, 21000 DIJON

Description

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. The company's mission is to develop and provide innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis in cancer. OPM focuses on creating value through a patient-centric and translational approach, collaborating with clinicians, service providers, and experts. Its core activities are centered on discovering new treatments for resistant and metastatic cancers, aiming to identify the most effective therapeutic pathways for patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-11 18:00
Informations privilégiées / Autres communiqués
French 466.5 KB
2025-05-06 18:00
Informations privilégiées / Autres communiqués
French 216.8 KB
2025-04-17 18:00
Inside Information / Other news releases
English 341.8 KB
2025-04-17 18:00
Informations privilégiées / Autres communiqués
French 331.1 KB
2025-04-03 18:00
Informations privilégiées / Communiqué sur comptes, résultats
French 364.7 KB
2025-04-03 18:00
Inside Information / News release on accounts, results
English 379.5 KB
2025-03-24 18:11
Informations privilégiées / Autres communiqués
French 540.6 KB
2025-03-24 18:11
Inside Information / Other news releases
English 629.3 KB
2025-03-04 17:45
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
French 293.7 KB
2025-03-04 17:45
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
English 287.9 KB
2025-01-08 18:00
Informations privilégiées / Autres communiqués
French 604.4 KB
2024-12-20 08:00
Inside Information / Other news releases
English 296.9 KB
2024-12-20 08:00
Informations privilégiées / Autres communiqués
French 284.3 KB
2024-10-22 18:00
Inside Information / Other news releases
English 310.0 KB
2024-10-22 18:00
Informations privilégiées / Autres communiqués
French 312.5 KB

Automate Your Workflow. Get a real-time feed of all Oncodesign Precision Medicine S.A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncodesign Precision Medicine S.A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncodesign Precision Medicine S.A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.